(firstQuint)Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes.

 This is a phase 3 trial to evaluate the safety and efficacy of YH14755 in subjects with dyslipidemia and Type II Diabetes.

 In YH14755 treatment group, 88 subjects will be assigned and the subjects administer YH14755 for 16 weeks.

 In Metformin treatment group, 88 subjects will be assigned and the subjects administer Metformin for 16 weeks.

 In Rosuvastatin treatment group, 88 subjects will be assigned and the subjects administer Rosuvastatin for 16 weeks.

.

 Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes@highlight

Randomized, double-blind, active-controlled, multicenter phase 3 trial to evaluate the safety and efficacy of YH14755 in subjects with dyslipidemia and Type II Diabetes.

